Abstract
Background
Immunotherapy has shown promise in the treatment of esophageal cancer, but using it alone only benefits a small number of patients. Most patients either do not have a significant response or develop secondary drug resistance. The combination of radiotherapy and immunotherapy appears to be a promising approach to treating esophageal cancer.
Purpose
We reviewed milestone clinical trials of radiotherapy combined with immunotherapy for esophageal cancer. We then discussed potential biomarkers for radiotherapy combined with immunotherapy, including programmed cell death-ligand 1 (PD-L1) status, tumor mutation burden (TMB), tumor-infiltrating lymphocytes, ct-DNA, imaging biomarkers, and clinical factors. Furthermore, we emphasize the key mechanisms of radiation therapy-induced immune stimulation and immune suppression in order to propose strategies for overcoming immune resistance in radiation therapy (RT). Lastly, we discussed the emerging role of low-dose radiotherapy (LDRT) , which has become a promising approach to overcome the limitations of high-dose radiotherapy.
Conclusion
Radiotherapy can be considered a triggering factor for systemic anti-tumor immune response and, with the assistance of immunotherapy, can serve as a systemic treatment option and potentially become the standard treatment for cancer patients.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Background
Despite significant progress in the treatment of esophageal cancer, its efficacy remains unsatisfactory. Immunotherapy, particularly immune checkpoint inhibitors (ICIs), has emerged as a promising new treatment strategy, completely changing the treatment prospects for esophageal cancer. However, the use of single-agent ICI method is limited to a response rate of only around 20% (Kato et al. 2019; Kojima et al. 2020; Huang et al. 2020; Shen et al. 2022). To overcome this limitation, researchers have explored the combination of immunotherapy with other treatment modalities. Radiation therapy is a widely used method for esophageal cancer at various stages, and when combined with immunotherapy, it has garnered considerable attention. The KEYNOTE-001 study revealed significant efficacy of ICIs in patients who had previously received radiation therapy (Shaverdian et al. 2017). Through the synergistic effect of immunotherapy and radiation therapy, the aim is to enhance the immune response against cancer cells while precisely targeting the tumors. Although further extensive multicenter studies are needed to validate these findings, the combination of immunotherapy and radiation therapy represents a promising approach that can reshape the treatment paradigm for esophageal cancer, providing new hope for patients and further advancing the field of oncology.
Research has shown that immunotherapy enhances immune responses by enhancing co-stimulatory signals, restoring immune surveillance, and promoting the destruction of cancer cells. Co-stimulatory signals primarily involve positive co-stimulatory factors (CD27, CD28, CD137) and negative co-stimulatory factors (CTLA-4, PD-1, PD-L1) pathways (Rowshanravan et al. 2018; Hosseini et al. 2020). Tumor cells activate immune checkpoints by binding to PD-1 and PD-L1, which hinders antigen presentation and evades attacks from T cells (Zheng et al. 2021; Ai et al. 2020). Immune checkpoint inhibitors (ICIs) block the interaction between PD-1 and PD-L1, promote T cell activation, and enhance their anti-tumor efficacy. Previous studies have demonstrated that stereotactic body radiation therapy (SBRT), as a form of precise radiation therapy, can promote the release of tumor antigens, leading to a phenomenon known as the “abscopal effect” (Theelen et al. 2019). The combination of ICIs and radiotherapy enhances local therapeutic efficacy by promoting antigen release, improving antigen presentation, and modifying the tumor microenvironment (Sardaro et al. 2021).
The impact of radiotherapy on the immune response in esophageal cancer has been studied. Du et al. (2022) performed fractionated irradiation on two human esophageal cancer cell lines (KYSE450, OE21), with a dose of 30 Gy/10 F, administered 5 times per week, to study changes in immune activity. The study found that radiotherapy can regulate the expression of interferons and affect signaling pathways such as STING–IFNAR1–STAT1–IRF1, resulting in enhanced immune responsiveness. When the irradiation dose was 30 Gy/10 F, the immune response of the cells and the formation of micronuclei significantly increased. In addition, genes associated with the STING–IFNAR1–STAT1–IRF1 pathway, MHC class I and II, as well as PD-L1 expression, were significantly upregulated. Zhang et al. (2017) used a 6-MV linear accelerator to irradiate three esophageal squamous cell lines (KYSE30, TE1, CaEs17) at doses of 0, 2, 4, and 8 Gy. The study showed that the expression of PD-L1 on the surface of tumor cells increased in a dose-dependent manner after radiation exposure, possibly related to the secretion of gamma interferon by CD8 + T lymphocytes and activation of the JAK-STAT pathway (Dovedi et al. 2014). These findings emphasize the impact of radiotherapy on immune-related mechanisms and provide insights into exploring the combined use of radiotherapy and immunotherapy in the treatment of esophageal cancer.
The aforementioned preclinical studies indicate that radiotherapy plays a crucial role in upregulating the expression of PD-L1 in the tumor microenvironment, thereby enhancing the efficacy of immune checkpoint inhibitors. A study conducted by Lim et al. (2016) supports this notion, as it observed a significant increase in PD-L1 expression (p = 0.007) in locally advanced esophageal squamous cell carcinoma (ESCC) patients after neoadjuvant chemoradiotherapy, highlighting the potential of this combination therapy. However, due to limitations such as small sample size, strict patient selection, and short follow-up time, these findings still require further well-designed multicenter studies to validate them and establish optimal treatment strategies to improve clinical outcomes.
Esophageal cancer is a highly heterogeneous disease (Dinh et al. 2021; Yan et al. 2019; Li et al. 2023; Krug and Michl 2017), with patients exhibiting diverse biological, clinical, genetic, and environmental characteristics. Existing treatment approaches for esophageal cancer are based on average results from previous clinical trials and typically follow traditional strategies involving radiotherapy and immunotherapy. However, given the high heterogeneity of the disease, it is crucial to consider the specificity of individual patients and replace a "one-size-fits-all" approach with personalized methods when it comes to combination therapies.
This article provides a review of the current research status of combined radiotherapy and immunotherapy in the treatment of esophageal cancer, and explores various aspects related to its therapeutic efficacy. We investigate the mechanisms of effectiveness in this combination therapy and discuss the limitations of existing treatment strategies. Clearly, optimizing precision treatment is crucial for addressing the heterogeneity of esophageal cancer. By customizing treatment plans to accommodate the specific characteristics of each patient, better outcomes can be achieved. Further research in this field holds great promise for advancing the field and improving treatment outcomes for patients.
Current status
In 2012, Postow et al. (2012) first reported a case of malignant melanoma in which a combination of ipilimumab and radiotherapy was used for treatment. Not only did the primary lesion completely regress, but even tumors outside the radiation field (such as right hepatic lymph nodes and spleen) also completely disappeared. In recent years, with the deepening of research on T cell regulation mechanisms, an increasing number of immune checkpoint inhibitors have been developed, showing remarkable efficacy in clinical studies targeting various malignancies (including tumors previously considered immune-resistant). These pioneering studies on combined radiotherapy and immunotherapy have spurred further clinical research in the field of esophageal cancer. Most recently, a phase II clinical trial, EC-CRT-001, conducted a single-arm study on locally advanced esophageal squamous cell carcinoma patients who were not eligible for surgical resection. The trial investigated the combination therapy of pembrolizumab (a PD-1 inhibitor) with chemoradiotherapy. Among the patients enrolled in the trial, 62% achieved complete remission, with a 1-year overall survival rate of 78.4% and a 1-year progression-free survival rate of 54.5%. Compared to traditional treatment methods, this approach has demonstrated significant efficacy and acceptable side effects for patients with locally advanced esophageal squamous cell carcinoma (Zhu et al. 2023). Another clinical trial, PALACE-1, treated 20 patients with resectable esophageal squamous cell carcinoma using preoperative pembrolizumab (PD-1 inhibitor) with concurrent chemoradiotherapy (PPCT) method. The results showed that 65% of patients experienced grade III or higher adverse events, with lymphocytopenia being the most common (92%). Among the 18 patients who underwent surgical treatment, the pathologic complete response (pCR) rate reached 55.6%. The study demonstrated that PPCT treatment has potential advantages in terms of safety and achieving pCR in resectable cases (Li et al. 2021). The results suggest that both trastuzumab and pembrolizumab treatments are safe and feasible adjuvant therapies for locally advanced esophageal cancer patients.
Systematic searches were performed in ClinicalTrial.gov databases up to June 2023 to gather information on clinical trials that explore the efficacy of the combination of radiotherapy and ICIs for the treatment of esophagus cancer. Table 1 presents a summary of the recent clinical trials of radiotherapy combined with immunotherapy. Currently, several prospective, multicenter, randomized clinical trials on radiotherapy combined with immune checkpoint inhibitors for the treatment of esophageal cancer are still ongoing. It is expected that in the near future, the safety and efficacy of combined radiochemotherapy with immune checkpoint inhibitors and neoadjuvant therapy will become clearer. This will contribute to further refinement and standardization of clinical radiochemotherapy combined with immunotherapy regimens.
Patient choice and biomarkers: updates and challenges
In recent years, the combined application of radiation therapy and immunotherapy has shown promising prospects in the treatment of tumors. However, it is important to recognize that this combination therapy may not yield the same clinical outcomes for all patients. Several factors contribute to the heterogeneity of immune therapy responses, including clinical and pathological factors, age, physical condition, and disease burden. To address this issue, researchers have been exploring the use of biomarkers to predict the efficacy of immune radiotherapy and to classify patients into different response and risk levels, ultimately aiding in the selection of personalized treatment strategies. We have summarized emerging biomarkers for predicting the efficacy of immune radiotherapy.
PD-L1
PD-L1 is currently considered the most widely accepted biomarker for predicting the efficacy of immunotherapy (Luchini et al. 2019; Gibney et al. 2016). For patients with high expression of PD-L1, standalone immunotherapy appears to provide a higher treatment effect, suggesting that they may not need radiation therapy to control the disease. Conversely, patients with low expression of PD-L1 may benefit from radiation therapy to achieve disease control, as their response to standalone immunotherapy may be lower (Theelen et al. 2021). The combination of radiation therapy and immunotherapy for patients with low PD-L1 expression may improve the treatment effect by enhancing disease control and bolstering immune response. Considering the individualized treatment strategy based on PD-L1 expression levels and the potential benefits of radiation therapy helps optimize treatment decisions and improve patient outcomes.
TMB
Tumor mutation burden (TMB) has the potential to serve as an important biomarker for predicting the response to immunotherapy, and its correlation with response rates to anti-PD-1 or anti-PD-L1 treatment has been confirmed in several types of tumors (Yarchoan et al. 2017; Lu et al. 2019; Chan et al. 2019). In numerous comparative trials evaluating the efficacy of immunotherapy and chemotherapy, TMB has shown prospects as an independent predictive biomarker (Yan et al. 2022; de Klerk et al. 2021). However, the role of TMB in predicting the efficacy of radiation therapy remains uncertain. In clinical studies exploring the combination of immunotherapy and radiation therapy for esophageal cancer, the assessment of TMB has not yet been uniformly incorporated. Further research is needed to determine the impact of TMB on radiation therapy outcomes and the potential inclusion of TMB in the decision-making for immune-radiation combination treatments. Understanding the relationship between TMB, immunotherapy, and radiation therapy can strengthen the selection strategies and optimize treatment methods for patients with esophageal cancer.
Tumor-infiltrating lymphocytes
Immune checkpoint inhibitors require lymphocytes to be adequately infiltrated in tumor tissue to exert their anti-tumor effects. Radiation therapy can stimulate local innate and adaptive immune responses by increasing the infiltration of tumor-infiltrating lymphocytes (TILs). Therefore, the composition, density, functional status, and tissue characteristics of TILs can serve as predictive indicators of the response to radiation and immunotherapy (Miller et al. 2019). CD8 + T cells play a crucial role in tumor clearance, and their infiltration is positively correlated with improved prognosis. Studies have shown that higher levels of PD-1 + CD8 + T cells in the tumor microenvironment can predict better outcomes for esophageal cancer patients receiving PD-1/PD-L1 inhibitor therapy (Zhang et al. 2021; Wu et al. 2020). Conversely, myeloid-derived suppressor cells (MDSCs), regulatory T cells (Tregs), tumor-associated macrophages, and neutrophils are enriched in the tumor microenvironment, negatively impacting prognosis due to their inhibitory effects on immune response (Kalathil and Thanavala 2021; Shang et al. 2015). Direct assessment of TILs remains challenging due to limited availability of histological material obtained from biopsies and the variability of the microenvironment at different metastatic sites. Ongoing research focuses on establishing and validating guidelines for TIL assessment.
ctDNA
Circulating tumor DNA (ctDNA) originates from tumor cells and contains genomic information of the tumor (Thurin et al. 2020). ctDNA can be a reliable tool for prognostic stratification after radiotherapy/radiochemotherapy. ctDNA assessment has potential in selecting appropriate candidates for adjuvant therapy after surgery and determining consolidation therapy after radiotherapy/radiochemotherapy (Wang et al. 2022a). Recent studies have shown that ctDNA levels can predict disease progression after immunotherapy and can be used to monitor early response to anti-PD-1 immunotherapy, closely correlating with progression-free survival (PFS) and overall survival (OS) (Cabel et al. 2017; Khagi et al. 2017; Keller et al. 2019). These findings suggest that ctDNA has the potential to serve as a non-invasive monitoring tool for evaluating treatment response and prognosis in patients with esophageal cancer undergoing radiotherapy combined with immunotherapy.
The predictive value of ctDNA in radiotherapy is still unclear. Existing evidence suggests that ctDNA levels increase shortly after radiation (Kageyama et al. 2018) but data from related studies are limited, making it impossible to reach a consensus on its predictive value. Further research and more evidence are needed to determine the true potential of ctDNA as a predictive biomarker for radiotherapy.
Imaging biomarkers
Functional imaging techniques such as PET-CT and MRI play a crucial role in predicting treatment response and evaluating prognosis in cancer patients. Optimizing these techniques and parameters is essential for improving prediction accuracy (Sakin et al. 2022; Lee et al. 2021; Borggreve et al. 2018). Clinical trials have demonstrated the efficacy of imaging responses in guiding treatment decisions (Goodman et al. 2021). Based on standard uptake values (SUV), tumor metabolic volume (MTV), and tumor glycolysis (TLG) determined by 18F-fluoro-2-deoxyglucose (18F-FDG) positron emission tomography (PET), they are associated with high levels of PD-L1 and the expression of PD-1, CD8, CD163 (tumor-associated macrophages), and Foxp3 (Tregs) TILs (tumor-infiltrating lymphocytes), suggesting the potential of metabolic parameters as prognostic biomarkers (Castello et al. 2020; Takada et al. 2017). Therefore, increasing research attempts to validate the predictive role of tumor metabolic variables in immunotherapy (Castello et al. 2020; Seban et al. 2020). By combining functional imaging with other biomarkers and ongoing research, personalized treatment for cancer can be advanced.
Clinical factors
Advanced esophageal cancer exhibits heterogeneity in terms of organ metastasis and lymph node involvement, resulting in differences in the effectiveness of radiotherapy treatment. For patients with advanced esophageal cancer, in addition to standard treatment, active primary tumor radiotherapy has also shown positive results (Guttmann et al. 2017). Real-world studies have shown that the addition of radiotherapy to immunotherapy can significantly prolong the overall survival (OS) of patients with locally recurrent esophageal cancer. In the overall patient cohort, there was no statistically significant difference in progression-free survival (PFS) and OS between patients who received radiotherapy and those who did not (Wu et al. 2023), highlighting the importance of patient selection. Advanced esophageal cancer with limited metastasis and regional lymph node recurrence has a better prognosis, and the combination of active local and systemic treatments may provide an opportunity for curative treatment, which should be considered when choosing treatment options for patients. Decision tree models have been used to classify oligometastatic esophageal cancer into different risk groups, identifying high-risk patients who may benefit from early intensified treatment such as immunotherapy and concurrent chemoradiotherapy (Shi et al. 2022). Overall, the research results emphasize the importance of tailoring treatment plans based on individual characteristics of patients with advanced esophageal cancer, including the extent of organ metastasis, lymph node involvement, and recurrence patterns. Active primary tumor radiotherapy, combined with local and systemic treatments, offers a promising strategy for improving the prognosis of specific patients.
The issues and challenges of radiotherapy combined with immunotherapy in the clinical treatment of esophageal cancer
Despite the combination of radiotherapy and immunotherapy being regarded as an effective new strategy for cancer treatment, its applicability remains somewhat controversial. Relevant research indicates that multiple factors may influence the efficacy of radiotherapy combined with immunotherapy.
The toxicity and safety of combination therapy are yet to be clarified
A large number of clinical studies have found that the use of immunomodulatory agents alone can cause serious adverse reactions, including fulminant myocarditis with rhabdomyolysis, immune-related pneumonia, and interstitial pneumonia (Brown et al. 2021). In combination therapy, the incidence of high-grade adverse events ranges from 20 to 50%, with lymphocyte reduction being the most common, followed by esophagitis, anastomotic leak, and esophageal fistula (Duan et al. 2023; Wang et al. 2022b; Wu et al. 2022; Sha et al. 2020; Zhou et al. 2021; Voong et al. 2019). According to data from the US Food and Drug Administration, the incidence of grade 3–4 pneumonia in patients who did not receive radiotherapy, received immune checkpoint inhibitors (ICI) within 90 days after radiotherapy, and received ICI more than 90 days after radiotherapy was 1.1%, 1.9%, and 1.2%, respectively. Although combining radiotherapy with ICI may increase the incidence of severe radiation pneumonitis, the absolute increase percentage is small, indicating that ICI administration within 90 days after radiotherapy appears to be safe (Anscher et al. 2022). In patients receiving neoadjuvant chemoradiotherapy with or without immunotherapy, there was no statistical difference in major complications (such as pulmonary complications, anastomotic leak, and other complications) as well as the risk of death or readmission (Sihag et al. 2021). However, it has been reported that 61% of patients with a history of immune-related adverse events developed grade 2 or higher radiation pneumonitis following radiotherapy, and 83% of patients with previous ICI-associated pneumonia developed grade 2 or higher radiation pneumonitis (Shaverdian et al. 2020). A retrospective study also found that combining radiotherapy with anti-PD-1 increased the incidence of esophageal perforation (18% vs. 3.1%, p = 0.002) (Peng et al. 2021). Although most clinical trials consider the safety of combination therapy acceptable, the enrolled population usually has lower tumor burden and better performance status, which may not accurately reflect the occurrence of immune-related adverse events in routine clinical practice.
The sequential regimen of combined radiotherapy and immunotherapy is still uncertain.
The integration of radiotherapy with immune checkpoint inhibitors (ICI) is a promising approach in cancer treatment, and various combination therapy modes have been explored. The three main approaches include synchronous ICI and radiotherapy, consolidation therapy with ICI after radiotherapy, and radiotherapy after induction with ICI. The theoretical separation of radiotherapy and ICI may potentially reduce adverse reactions. However, determining the optimal timing and interval between radiotherapy and ICI remains a challenge. Limited data are available for combined therapy in esophageal cancer. In this case, insights from lung cancer treatment can guide decision-making. The PACIFIC study demonstrated a slight improvement in outcomes for patients who started using Durvalumab within 2 weeks after radiotherapy (Antonia et al. 2018). Similarly, real-world PACIFICC-R study showed better prognosis for patients who initiated Durvalumab treatment within 42 days compared to those with delayed initiation (Girard et al. 2023). Meta-analysis suggests that the interval between radiotherapy and Durvalumab exceeds 42 days in real-world practice, with no significant impact on progression-free survival (PFS) or overall survival (OS) at 12 months (Wang et al. 2022c). Ongoing clinical trials for consolidation therapy in esophageal squamous cell carcinoma typically adopt a 6-week interval between the end of radiotherapy and the start of ICI. In cases involving esophagectomy and adjuvant immunotherapy, a longer interval may be required for immune system recovery (Kelly et al. 2021). It should be noted that the timing of initiating ICI after neoadjuvant chemoradiotherapy and curative surgery affects survival benefits. In patients with recurrent metastatic esophageal squamous cell carcinoma, median PFS and OS were prolonged in patients who received radiotherapy within 90 days before or after immunotherapy treatment (Wu et al. 2023). A multicenter retrospective study in Italy found that an interval of less than 7 days between stereotactic body radiotherapy (SBRT) and ICI prolonged OS, with slightly higher but manageable toxicity (Duan et al. 2023; Scoccianti et al. 2021). However, the most effective regimen for ICI combined with radiotherapy remains unclear and may vary depending on specific multimodal treatments and cancer types.
The sequencing of radiotherapy and immunotherapy is a key aspect of the treatment plan in radioimmunotherapy. In mouse models, simultaneous or short-term administration of PD-1 inhibitors after local radiotherapy has shown potential in enhancing intra-tumoral expansion of multifunctional CD8 + T cells and reducing peripheral CD8 + T cell death, thereby generating a more favorable systemic anti-tumor response and distant effects (Dovedi et al. 2014; Wei et al. 2021). Patients who receive immune checkpoint inhibitors (ICI) after stereotactic body radiotherapy (SBRT) or stereotactic radiosurgery (SRS), or concurrently with these treatments, also show improved outcomes (Woody et al. 2022; Kiess et al. 2015; Schoenfeld et al. 2015), possibly due to the release of new antigens induced by radiotherapy and increased PD-L1 expression. However, some studies have found no statistically significant difference between simultaneous and sequential administration (Welsh et al. 2019). Further research is needed to determine the optimal treatment sequence for different combinations and types of tumors.
Most studies tend to administer immune checkpoint inhibitors (ICI) simultaneously with or sequentially after radiotherapy. However, there are reports indicating that post-radiotherapy administration of anti-PD-1 agents in esophageal cancer may increase the risk of perforation and requires close monitoring (Peng et al. 2021). For patients with specific characteristics such as ulcerative, large, thin-walled, or invasion into major blood vessels, considering induction immunotherapy as first-line treatment may be an option. Induction immunotherapy can help alleviate symptoms, improve nutritional status, reduce irradiated volume, minimize side effects, and provide better protection to surrounding normal tissues.
In summary, although the integration of radiotherapy and immune checkpoint inhibitors (ICI) holds promise in cancer treatment, determining the optimal timing and interval between these modalities remains an ongoing area of research. Developing individualized treatment plans based on specific cancer types, neoadjuvant or adjuvant treatment settings, and patient characteristics is crucial for maximizing treatment efficacy.
There is currently no standardized approach for determining the optimal dose and fractionation of radiotherapy in combination therapy
There has been ongoing controversy over the optimal dosage for esophageal cancer radiation therapy. However, in recent years, with the strengthening of systemic therapy, several large-scale phase III studies have compared the efficacy and safety of 50 Gy radiation dosage for esophageal squamous cell carcinoma with higher dosages (Hulshof et al. 2021; Xu et al. 2022; Minsky et al. 2002; Crehange et al. 2021). Currently, 50 Gy is the recommended dosage for radical radiotherapy for esophageal squamous cell carcinoma (Ajani et al. 2023). Guidelines suggest a radiation dosage range of 41.4–50.4 Gy for neoadjuvant radiotherapy. Studies have shown that higher radiation doses do not necessarily improve treatment outcomes or patient prognosis (Worrell et al. 2020). The CROSS (Chemoradiotherapy for Oesophageal Cancer followed by Surgery Study) regimen, with a dosage of 41.4 Gy administered in 23 fractions, has been widely adopted in neoadjuvant therapy due to its favorable effects. The SCALE study explored a shorter neoadjuvant radiotherapy course of 30 Gy/12F and achieved a 55% pathological complete response (pCR) rate (Jiang et al. 2022). In the NICE-RT study, the primary lesion and adjacent lymph nodes were conventionally fractionated with 41.4 Gy/23 fractions, while the distant lymph nodes received low-dose radiation of 0.5 Gy four times. For metastatic esophageal squamous cell carcinoma, radical or neoadjuvant radiotherapy regimens are commonly used for the primary lesion. Treatment strategies for metastatic lesions vary, including attempts at low-dose radiation (Herrera et al. 2022a), different dosage combinations, and SBRT/SRS techniques. The combination of high-dose and low-dose treatments (20–70 Gy, 3–12.5 Gy per session; 1–10 Gy, total dose of 0.5–2 Gy per session) has been shown to potentially reverse immune resistance after immunotherapy.
Overcoming immunotherapy resistance with radiotherapy: updates and challenges
Radiation therapy (RT) can directly destroy tumor cells and induce immune-mediated anti-tumor effects, as well as improve the tumor microenvironment (Formenti and Demaria 2009; Burnette et al. 2012; Rückert et al. 2021a; Brix et al. 2017; Meric-Bernstam et al. 2021). Localized radiation therapy can trigger tumor cell death, while releasing cytokines, chemokines, tumor antigens, and damage-associated molecular patterns (DAMPs) signals. These signals can enhance the function of antigen-presenting cells (APCs), activate tumor-specific T cell immunity, and promote APC recruitment. In addition, localized radiation therapy can also promote the expression of major histocompatibility complex (MHC) and loading of tumor antigens onto APCs. These antigen-loaded APCs will migrate to draining lymph nodes, stimulating the activation of immune responses, enhancing T cell proliferation, and improving their ability to recognize tumors (Formenti and Demaria 2009, 2013; Ahmed et al. 2013; Voorwerk et al. 2019). However, radiation therapy may also induce immune suppression in the tumor microenvironment by activating immune inhibitory factors such as transforming growth factor-beta (TGF-β), regulatory T cells (Tregs), tumor-associated macrophages (TAMs), and myeloid-derived suppressor cells (MDSCs). At the same time, the expression of programmed cell death-ligand 1 (PD-L1) in tumor cells is upregulated, which is closely related to the phenomenon of immune suppression in the tumor site (Yin et al. 2019; Zhai et al. 2022; Wang and Haffty 2018; Tagliaferri et al. 2022; Kho et al. 2021) (Fig. 1). Understanding the dual mechanism of localized radiation therapy in tumor immunity is crucial for developing strategies to optimize treatment efficacy and enhance overall anti-tumor immune responses.
In the treatment of oligometastatic lesions in advanced esophageal cancer with SBRT, a phenomenon known as the "abscopal effect" (Zhao et al. 2018) has been observed, where non-irradiated lesions also show shrinkage or regression. In recent years, a significant amount of research has been focused on studying the potential of combining radiation therapy with immunotherapy to induce the abscopal effect (Ngwa et al. 2018; Liu et al. 2018; Kodet et al. 2021; Wang et al. 2020; Buchwald et al. 2018). The abscopal effect is based on radiation therapy killing tumor cells, leading to the release of tumor-associated antigens (TAAs), which are subsequently captured by dendritic cells (DCs). DCs activate CD8 T cells, induce systemic immune responses, control tumor proliferation, and generate therapeutic effects in distant sites (Hu et al. 2017; Siva et al. 2015; Weichselbaum et al. 2017). Understanding and harnessing the abscopal effect may bring revolutionary changes to the treatment of advanced cancer, potentially improving outcomes and expanding disease control.
Higher single radiation doses may better support immune-induced mechanisms (Marconi et al. 2017), but they can also lead to serious adverse effects such as esophageal bleeding and perforation. This high-dose radiation in a single fraction is not suitable for the treatment of primary tumors in esophageal cancer. Therefore, currently, conventional low-dose radiation therapy is preferred in the treatment of esophageal cancer to minimize severe adverse effects.
The ongoing study NCT02642809 (NCT02642809: Pembrolizumab With Locally Delivered Radiation Therapy for the Treatment of Metastatic Esophageal Cancers) is a Phase I study conducted at a single institution, using an open-label design and a single dose level. Its primary objective is to evaluate the tolerability of high-dose radiotherapy combined with pembrolizumab in the treatment of metastatic esophageal cancer. The study utilizes hypofractionated radiotherapy (16 Gy in 2 fractions, with a 7–10 day interval between fractions) followed by pembrolizumab (200 mg, once every 3 weeks, starting within 1 week after completion of the short-range radiotherapy, and continuing for 8 months). The aim is to deliver an adequate dose of radiation to induce the release of tumor-derived antigens and trigger anti-tumor immune responses. The tolerability of the treatment will be measured by the incidence of treatment-related adverse events (TRAEs). This study aims to promote the use of immune-combined radiotherapy as a unique strategy for the treatment of advanced esophageal cancer. Conventional low-dose radiotherapy combined with immunotherapy for primary tumors and oligometastatic radiotherapy combined with immunotherapy for late-stage tumors may become the main treatment strategies for esophageal cancer.
Clinical pre-studies have shown that the phenomenon of distant tumor regression, known as the abscopal effect, occurs in immunocompetent environments rather than in immunocompromised conditions (Stone et al. 1979; Park et al. 2014). The research results emphasize the critical role of anti-tumor immunity as a key factor influencing the effectiveness of radiation therapy. In a mouse model of fibrosarcoma, immunocompetent hosts were able to control the tumor at lower radiation doses compared to immunodeficient hosts (Stone et al. 1979). Similarly, in another study using a mouse model of melanoma (B16 tumor), immunocompetent hosts responded to high-dose radiation, while immunodeficient hosts showed no response to radiotherapy and had a higher propensity for tumor metastasis. This evidence highlights the importance of anti-tumor immunity in mediating the abscopal effect (Lee et al. 2009).
Different immune therapies may have different effects on the response of primary and distant tumor sites. For example, vaccination is an emerging area of research that has shown promising results for the future of immune therapy. Activated whole tumor cell vaccines can enhance the immune response induced by radiation therapy by inhibiting immune checkpoint molecules such as PD-1 (Rückert et al. 2021b). Recent studies have emphasized the importance of increased levels of novel oxidative phosphorylation (OXPHOS) in tumors, which is related to the efficacy of immune therapy (Pustylnikov et al. 2018; Chamoto et al. 2017), Anti-PD-1 antibodies or radiation therapy can increase OXPHOS levels (Chamoto et al. 2017; Ashton et al. 2018; Le et al. 2018). Therefore, combined treatment with radiation therapy and OXPHOS inhibitors may be an effective strategy against PD-1 resistance in esophageal cancer (Chen et al. 2020).
Understanding the immune mechanisms of radiation therapy is crucial in unleashing the potential and revolutionizing cancer treatment based on immune-combined radiation therapy. Through studying the immune mechanisms of radiation therapy, it contributes to the design and implementation of immune-combined radiation therapy, providing new avenues for personalized and targeted treatment of tumors.
Low-dose radiotherapy enhances the efficacy of immune-combined radiation therapy: updates and challenges
The adverse tumor microenvironment, such as vascular barriers, lack of appropriate cytokines and immune suppression factors, hinders T cell infiltration and thus impairs the effectiveness of immune therapy (Motz and Coukos 2013; Sharabi et al. 2015). High-dose radiation therapy, whether delivered conventionally or through stereotactic body radiation therapy (SBRT), can induce the production and release of cytokines and chemokines, creating an inflammatory microenvironment that promotes T cell infiltration and immunogenic cell death (McLaughlin et al. 2020; Darragh et al. 2018; Donlon et al. 2021). However, high-dose radiation therapy alone may not fully address immune suppression factors, such as inhibitory tumor microenvironment. Recent studies suggest that low-dose radiotherapy (LDRT) holds promise in addressing these limitations and improving the outcome of immune therapy. LDRT is typically defined as fractionated doses of 0.5–2 Gy and total doses of 1–10 Gy (Patel et al. 2021a; Menon et al. 2019; Yin et al. 2020; Barsoumian et al. 2020), which are generally considered non-cytotoxic but have the potential to modulate the tumor microenvironment and enhance T cell infiltration.
LDRT demonstrates additional synergistic effects supported by radiobiological data, including the phenomenon of radiation hypersensitivity, where even low doses of X-rays as low as 0.1 Gy can effectively induce tumor cell death. Dynamic microscopy imaging studies have confirmed the effectiveness of LDRT in real-time visualization experiments, providing evidence for its potential as a treatment strategy (Joiner et al. 2001; Short et al. 1999; Marples et al. 1997). In clinical research, the combination of LDRT with chemotherapy has shown significant tumor control rates, particularly when using doses that can induce radiation hypersensitivity (Mantini et al. 2012; Regine et al. 2007; Balducci et al. 2012). By combining LDRT with other treatments such as chemotherapy or immunotherapy, the synergistic effects can be utilized to improve cancer treatment outcomes.
LDRT has the potential to reshape the tumor microenvironment and facilitate T cell homing, providing new possibilities for enhancing immunotherapy. While high-dose fractionated radiotherapy has demonstrated in-situ vaccine effects and ex vivo effects, direct evidence for similar effects from low-dose radiation therapy is still limited. LDRT shows promise in patients lacking tumor-infiltrating CD8 T cells, as it can modulate the tumor microenvironment and facilitate T cell recruitment (Klug et al. 2013; Liu et al. 2019). LDRT plays a particularly vital role in the preparatory stage of combining immunotherapy to induce T cell homing.
Animal experiments have shown that low-dose radiotherapy (LDRT) combined with immune checkpoint inhibitors (ICIs) can better control tumors, including ovarian cancer, breast cancer, and gliomas, among others (Herrera et al. 2022a, b; Patel et al. 2021b). Among them, the combination of low-dose radiation therapy and PD-1 blockade achieved complete tumor remission in 85.7% of mice (Yin et al. 2020). Low-dose radiation (0.5–2 Gy) demonstrated evidence of tumor microenvironment (TME) reprogramming and induction of M1 macrophage polarization in a mouse model of localized pancreatic neuroendocrine tumors (Deloch et al. 2019; Nadella et al. 2018). iNOS-positive M1 macrophages play a crucial role in recruiting effector T cells, promoting tumor vascular normalization and inflammation, and facilitating T cell infiltration into the tumor microenvironment (Klug et al. 2013; Prakash et al. 2016; Palma et al. 2013). Combining high-dose irradiation of the primary tumor, low-dose radiation therapy of metastatic lesions, and immune checkpoint inhibitors in a mouse lung cancer model can effectively control metastatic tumors through immune response and downregulation of immunosuppressive factor TGF-β (Barsoumian et al. 2020).
Clinical studies have shown that LDRT, as a new adjuvant therapy for pancreatic cancer patients, can increase the ratio of iNOS macrophages to CD8 T cells and reduce tumor vessel diameter (Klug et al. 2013). Clinical trials of LDRT combined with immunotherapy in patients with peritoneal metastatic ovarian cancer have demonstrated that LDRT induces transient tumor inflammation, making it sensitive to immunotherapy (Herrera et al. 2022a). Conversely, LDRT may have inhibitory effects on inflammatory lesions driven by benign inflammation or autoimmune T cell-driven diseases (Rödel et al. 2012a, b). Further clinical research is needed to compare the impact of LDRT on the tumor microenvironment and determine the optimal dosage range for macrophage remodeling and enhanced T cell infiltration.
In the exploration of improving the efficacy of immunotherapy, the combination of low-dose radiotherapy (LDRT) and high-dose radiation therapy has emerged as a promising treatment strategy. Although LDRT cannot directly kill tumor cells, it has the potential to activate immune cells and modulate the tumor microenvironment, thereby enhancing the effectiveness of immunotherapy. Recent clinical trials have investigated the combination of stereotactic body radiation therapy (SBRT) and the immune checkpoint inhibitor ipilimumab in the treatment of advanced metastatic lesions. The results suggest that tumors exposed to LDRT exhibit higher treatment responses compared to distant tumors (Welsh et al. 2019). The combination of high-dose radiation and LDRT represents a new treatment approach, where high-dose radiation promotes antigen release and presentation, and activates immune cells, while LDRT facilitates immune cell infiltration into distant tumor microenvironments (Menon et al. 2019). The results of a non-randomized phase II trial combining LDRT, high-dose radiation, and immunotherapy showed that disease regions exposed to LDRT were more likely to generate local responses (Patel et al. 2021). Future clinical trials should compare the efficacy of different LDRT regimens in combination with immune checkpoint inhibitors (ICIs) to determine the optimal approach. These strategies can serve as palliative treatment options for refractory patients, reshaping the tumor microenvironment and inducing new anti-tumor responses. The combination of high-dose SBRT triggering in-situ vaccine effects at limited metastatic sites, along with LDRT targeting other metastatic sites to activate T cells, holds the potential to maximize distant effects.
Low-dose radiotherapy (LDRT) has emerged as a promising approach to overcome the limitations of high-dose radiation therapy. High radiation doses at the primary site of esophageal cancer can lead to serious adverse effects such as bleeding and perforation. Therefore, combining high-dose radiation therapy for distant metastases with low-dose radiation therapy at the primary site may be a new treatment method for advanced esophageal cancer. Although further research is needed to fully explore its capabilities, LDRT has the potential to become an important avenue for future investigations. By optimizing the use of radiation therapy, particularly at low doses, we can improve treatment effectiveness and explore new possibilities in cancer management.
Conclusion
The potential of radioimmunotherapy in improving the prognosis of esophageal cancer patients is exciting. Large-scale studies are currently underway to explore various aspects, such as radiation dosage, fractionation, irradiation sites and techniques, timing and duration of combined therapy, and the selection of immunotherapy agents, with the aim of uncovering its anti-tumor mechanisms and predictive biomarkers to enhance treatment efficacy. Radioimmunotherapy may present a new approach for patients with locally advanced or metastatic esophageal cancer, especially when combined with ICIs and low-dose radiation, as it can induce a systemic anti-tumor response. As immunotherapy plays an increasingly important role in solid tumor treatment, leveraging the synergistic advantages between radiation therapy and immunotherapy could open up new avenues for the design of combination immunotherapy.
Availability of data and materials
Not applicable.
Abbreviations
- APCs:
-
Antigen-presenting cells
- ctDNA:
-
Circulating tumor DNA
- DAMPs:
-
Damage-associated molecular patterns
- DCs:
-
Dendritic cells
- ESCC:
-
Esophageal squamous cell carcinoma
- ICIs:
-
Immune checkpoint inhibitors
- LDRT:
-
Low-dose radiotherapy
- MDSCs:
-
Myeloid-derived suppressor cells
- MDSCs:
-
Myeloid-derived suppressor cells
- MHC:
-
Major histocompatibility complex
- OS:
-
Overall survival
- pCR:
-
Pathologic complete response
- PD‐1:
-
Programmed cell death protein 1
- PD‐L1:
-
Programmed cell death protein ligand 1
- PFS:
-
Progression-free survival
- RT:
-
Radiation therapy
- SBRT:
-
Stereotactic body radiation therapy
- SRS:
-
Stereotactic radiosurgery
- TAAs:
-
Tumor-associated antigens
- TAMs:
-
Tumor-associated macrophages
- TGF-β:
-
Transforming growth factor-beta
- TILs:
-
Tumor-infiltrating lymphocytes
- TMB:
-
Tumor mutational burden
- TME:
-
Tumor microenvironment
- TRAEs:
-
Treatment-related adverse events
- Tregs:
-
Regulatory T cells
References
Ahmed MM, Hodge JW, Guha C, Bernhard EJ, Vikram B, Coleman CN (2013) Harnessing the potential of radiation-induced immune modulation for cancer therapy. Cancer Immunol Res 1(5):280–284. https://doi.org/10.1158/2326-6066.CIR-13-0141
Ai L, Xu A, Xu J (2020) Roles of PD-1/PD-L1 pathway: signaling, cancer, and beyond. Adv Exp Med Biol 1248:33–59. https://doi.org/10.1007/978-981-15-3266-5_3
Ajani JA, D’Amico TA, Bentrem DJ et al (2023) Esophageal and esophagogastric junction cancers, version 2.2023, nccn clinical practice guidelines in oncology. J Natl Compr Canc Netw 21(4):393–422. https://doi.org/10.6004/jnccn.2023.0019
Anscher MS, Arora S, Weinstock C et al (2022) Association of radiation therapy with risk of adverse events in patients receiving immunotherapy: a pooled analysis of trials in the US Food and Drug Administration Database. JAMA Oncol 8(2):232–240. https://doi.org/10.1001/jamaoncol.2021.6439
Antonia SJ, Villegas A, Daniel D et al (2018) Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 379(24):2342–2350. https://doi.org/10.1056/NEJMoa1809697
Ashton TM, McKenna WG, Kunz-Schughart LA, Higgins GS (2018) Oxidative phosphorylation as an emerging target in cancer therapy. Clin Cancer Res 24(11):2482–2490. https://doi.org/10.1158/1078-0432.CCR-17-3070
Balducci M, Chiesa S, Diletto B et al (2012) Low-dose fractionated radiotherapy and concomitant chemotherapy in glioblastoma multiforme with poor prognosis: a feasibility study. Neuro Oncol 14(1):79–86. https://doi.org/10.1093/neuonc/nor173
Barsoumian HB, Ramapriyan R, Younes AI et al (2020) Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma. J Immunother Cancer. https://doi.org/10.1136/jitc-2020-000537
Borggreve AS, Mook S, Verheij M et al (2018) Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE): a multicenter observational study. BMC Cancer 18(1):1006. https://doi.org/10.1186/s12885-018-4892-6
Brix N, Tiefenthaller A, Anders H, Belka C, Lauber K (2017) Abscopal, immunological effects of radiotherapy: narrowing the gap between clinical and preclinical experiences. Immunol Rev 280(1):249–279. https://doi.org/10.1111/imr.12573
Brown TJ, Mamtani R, Bange EM (2021) Immunotherapy adverse effects. JAMA Oncol 7(12):1908. https://doi.org/10.1001/jamaoncol.2021.5009
Buchwald ZS, Wynne J, Nasti TH et al (2018) Radiation, immune checkpoint blockade and the abscopal effect: a critical review on timing, dose and fractionation. Front Oncol 8:612. https://doi.org/10.3389/fonc.2018.00612
Burnette B, Fu Y-X, Weichselbaum RR (2012) The confluence of radiotherapy and immunotherapy. Front Oncol 2:143. https://doi.org/10.3389/fonc.2012.00143
Cabel L, Riva F, Servois V et al (2017) Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study. Ann Oncol 28(8):1996–2001. https://doi.org/10.1093/annonc/mdx212
Castello A, Toschi L, Rossi S, Mazziotti E, Lopci E (2020) The immune-metabolic-prognostic index and clinical outcomes in patients with non-small cell lung carcinoma under checkpoint inhibitors. J Cancer Res Clin Oncol 146(5):1235–1243. https://doi.org/10.1007/s00432-020-03150-9
Chamoto K, Chowdhury PS, Kumar A et al (2017) Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity. Proc Natl Acad Sci USA 114(5):E761–E770. https://doi.org/10.1073/pnas.1620433114
Chan TA, Yarchoan M, Jaffee E et al (2019) Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol 30(1):44–56. https://doi.org/10.1093/annonc/mdy495
Chen D, Barsoumian HB, Fischer G et al (2020) Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity. J Immunother Cancer. https://doi.org/10.1136/jitc-2019-000289
Crehange G, M’vondo C, Bertaut A et al (2021) Exclusive chemoradiotherapy with or without radiation dose escalation in esophageal cancer: multicenter phase 2/3 randomized trial CONCORDE (PRODIGE-26). Int J Radiat Oncol Biol Phys 111(3):S5
Darragh LB, Oweida AJ, Karam SD (2018) Overcoming resistance to combination radiation-immunotherapy: a focus on contributing pathways within the tumor microenvironment. Front Immunol 9:3154. https://doi.org/10.3389/fimmu.2018.03154
de Klerk LK, Patel AK, Derks S et al (2021) Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival. J Immunother Cancer. https://doi.org/10.1136/jitc-2021-002472
De Palma M, Coukos G, Hanahan D (2013) A new twist on radiation oncology: low-dose irradiation elicits immunostimulatory macrophages that unlock barriers to tumor immunotherapy. Cancer Cell 24(5):559–561. https://doi.org/10.1016/j.ccr.2013.10.019
Deloch L, Fuchs J, Rückert M, Fietkau R, Frey B, Gaipl US (2019) Low-dose irradiation differentially impacts macrophage phenotype in dependence of fibroblast-like synoviocytes and radiation dose. J Immunol Res 2019:3161750. https://doi.org/10.1155/2019/3161750
Dinh HQ, Pan F, Wang G et al (2021) Integrated single-cell transcriptome analysis reveals heterogeneity of esophageal squamous cell carcinoma microenvironment. Nat Commun 12(1):7335. https://doi.org/10.1038/s41467-021-27599-5
Donlon NE, Power R, Hayes C, Reynolds JV, Lysaght J (2021) Radiotherapy, immunotherapy, and the tumour microenvironment: turning an immunosuppressive milieu into a therapeutic opportunity. Cancer Lett 502:84–96. https://doi.org/10.1016/j.canlet.2020.12.045
Dovedi SJ, Adlard AL, Lipowska-Bhalla G et al (2014) Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Can Res 74(19):5458–5468. https://doi.org/10.1158/0008-5472.CAN-14-1258
Du J, Kageyama S-I, Yamashita R et al (2022) Impacts of the STING-IFNAR1-STAT1-IRF1 pathway on the cellular immune reaction induced by fractionated irradiation. Cancer Sci 113(4):1352–1361. https://doi.org/10.1111/cas.15297
Duan Y, Qin W, Yang L et al (2023) Safety and efficacy of concurrent or sequential radiotherapy plus (PD-1) inhibitors in oligometastatic esophageal cancer. Cancer Manag Res 15:55–65. https://doi.org/10.2147/CMAR.S391529
Formenti SC, Demaria S (2009) Systemic effects of local radiotherapy. Lancet Oncol 10(7):718–726. https://doi.org/10.1016/S1470-2045(09)70082-8
Formenti SC, Demaria S (2013) Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst 105(4):256–265. https://doi.org/10.1093/jnci/djs629
Gibney GT, Weiner LM, Atkins MB (2016) Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol 17(12):e542–e551. https://doi.org/10.1016/S1470-2045(16)30406-5
Girard N, Bar J, Garrido P et al (2023) Treatment characteristics and real-world progression-free survival in patients with unresectable stage III NSCLC who received durvalumab after chemoradiotherapy: findings from the PACIFIC-R study. J Thorac Oncol 18(2):181–193. https://doi.org/10.1016/j.jtho.2022.10.003
Goodman KA, Ou F-S, Hall NC et al (2021) Randomized phase II study of PET response-adapted combined modality therapy for esophageal cancer: mature results of the CALGB 80803 (Alliance) trial. J Clin Oncol 39(25):2803–2815. https://doi.org/10.1200/JCO.20.03611
Guttmann DM, Mitra N, Bekelman J et al (2017) Improved overall survival with aggressive primary tumor radiotherapy for patients with metastatic esophageal cancer. J Thorac Oncol 12(7):1131–1142. https://doi.org/10.1016/j.jtho.2017.03.026
Herrera FG, Ronet C, Ochoa de Olza M et al (2022a) Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy. Cancer Discov 12(1):108–133. https://doi.org/10.1158/2159-8290.CD-21-0003
Herrera FG, Romero P, Coukos G (2022b) Lighting up the tumor fire with low-dose irradiation. Trends Immunol 43(3):173–179. https://doi.org/10.1016/j.it.2022.01.006
Hosseini A, Gharibi T, Marofi F, Babaloo Z, Baradaran B (2020) CTLA-4: from mechanism to autoimmune therapy. Int Immunopharmacol 80:106221. https://doi.org/10.1016/j.intimp.2020.106221
Hu ZI, McArthur HL, Ho AY (2017) The abscopal effect of radiation therapy: what is it and how can we use it in breast cancer? Curr Breast Cancer Rep 9(1):45–51. https://doi.org/10.1007/s12609-017-0234-y
Huang J, Xu J, Chen Y et al (2020) Camrelizumab versus investigator’s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. Lancet Oncol 21(6):832–842. https://doi.org/10.1016/S1470-2045(20)30110-8
Hulshof MCCM, Geijsen ED, Rozema T et al (2021) Randomized study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer (ARTDECO Study). J Clin Oncol 39(25):2816–2824. https://doi.org/10.1200/JCO.20.03697
Jiang N, Jiang M, Zhu X et al (2022) SCALE-1: safety and efficacy of short course neoadjuvant chemo-radiotherapy plus toripalimab for locally advanced resectable squamous cell carcinoma of esophagus. Am Soc Clin Oncol 40:4063
Joiner MC, Marples B, Lambin P, Short SC, Turesson I (2001) Low-dose hypersensitivity: current status and possible mechanisms. Int J Radiat Oncol Biol Phys 49(2):379–389
Kageyama S-I, Nihei K, Karasawa K et al (2018) Radiotherapy increases plasma levels of tumoral cell-free DNA in non-small cell lung cancer patients. Oncotarget 9(27):19368–19378. https://doi.org/10.18632/oncotarget.25053
Kalathil SG, Thanavala Y (2021) Importance of myeloid derived suppressor cells in cancer from a biomarker perspective. Cell Immunol 361:104280. https://doi.org/10.1016/j.cellimm.2020.104280
Kato K, Cho BC, Takahashi M et al (2019) Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 20(11):1506–1517. https://doi.org/10.1016/S1470-2045(19)30626-6
Keller L, Guibert N, Casanova A et al (2019) Early circulating tumour DNA variations predict tumour response in melanoma patients treated with immunotherapy. Acta Derm Venereol 99(2):206–210. https://doi.org/10.2340/00015555-3080
Kelly RJ, Ajani JA, Kuzdzal J et al (2021) Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 384(13):1191–1203. https://doi.org/10.1056/NEJMoa2032125
Khagi Y, Goodman AM, Daniels GA et al (2017) Hypermutated circulating tumor DNA: correlation with response to checkpoint inhibitor-based immunotherapy. Clin Cancer Res 23(19):5729–5736. https://doi.org/10.1158/1078-0432.CCR-17-1439
Kho VM, Mekers VE, Span PN, Bussink J, Adema GJ (2021) Radiotherapy and cGAS/STING signaling: impact on MDSCs in the tumor microenvironment. Cell Immunol 362:104298. https://doi.org/10.1016/j.cellimm.2021.104298
Kiess AP, Wolchok JD, Barker CA et al (2015) Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys 92(2):368–375. https://doi.org/10.1016/j.ijrobp.2015.01.004
Klug F, Prakash H, Huber PE et al (2013) Low-dose irradiation programs macrophage differentiation to an iNOS+/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell 24(5):589–602. https://doi.org/10.1016/j.ccr.2013.09.014
Kodet O, Němejcova K, Strnadová K et al (2021) The abscopal effect in the era of checkpoint inhibitors. Int J Mol Sci. https://doi.org/10.3390/ijms22137204
Kojima T, Shah MA, Muro K et al (2020) Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol 38(35):4138–4148. https://doi.org/10.1200/JCO.20.01888
Krug S, Michl P (2017) Esophageal cancer: new insights into a heterogenous disease. Digestion 95(4):253–261. https://doi.org/10.1159/000464130
Le M, McNeill FE, Seymour CB et al (2018) Modulation of oxidative phosphorylation (OXPHOS) by radiation-induced biophotons. Environ Res 163:80–87. https://doi.org/10.1016/j.envres.2018.01.027
Lee Y, Auh SL, Wang Y et al (2009) Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 114(3):589–595. https://doi.org/10.1182/blood-2009-02-206870
Lee S, Choi Y, Park G et al (2021) 18F-FDG PET/CT parameters for predicting prognosis in esophageal cancer patients treated with concurrent chemoradiotherapy. Technol Cancer Res Treat 20:15330338211024656. https://doi.org/10.1177/15330338211024655
Li C, Zhao S, Zheng Y et al (2021) Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1). Eur J Cancer 144:232–241. https://doi.org/10.1016/j.ejca.2020.11.039
Li J, Li L, You P, Wei Y, Xu B (2023) Towards artificial intelligence to multi-omics characterization of tumor heterogeneity in esophageal cancer. Semin Cancer Biol 91:35–49. https://doi.org/10.1016/j.semcancer.2023.02.009
Lim SH, Hong M, Ahn S et al (2016) Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer. Eur J Cancer 52:1–9. https://doi.org/10.1016/j.ejca.2015.09.019
Liu Y, Dong Y, Kong L, Shi F, Zhu H, Yu J (2018) Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. J Hematol Oncol 11(1):104. https://doi.org/10.1186/s13045-018-0647-8
Liu J, Zhou J, Wu M et al (2019) Low-dose total body irradiation can enhance systemic immune related response induced by hypo-fractionated radiation. Front Immunol 10:317. https://doi.org/10.3389/fimmu.2019.00317
Lu S, Stein JE, Rimm DL et al (2019) Comparison of biomarker modalities for predicting response to PD-1/PD-L1 checkpoint blockade: a systematic review and meta-analysis. JAMA Oncol 5(8):1195–1204. https://doi.org/10.1001/jamaoncol.2019.1549
Luchini C, Bibeau F, Ligtenberg MJL et al (2019) ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol off J Eur Soc Med Oncol 30(8):1232–1243. https://doi.org/10.1093/annonc/mdz116
Mantini G, Valentini V, Meduri B et al (2012) Low-dose radiotherapy as a chemo-potentiator of a chemotherapy regimen with pemetrexed for recurrent non-small-cell lung cancer: a prospective phase II study. Radiother Oncol 105(2):161–166. https://doi.org/10.1016/j.radonc.2012.09.006
Marconi R, Strolin S, Bossi G, Strigari L (2017) A meta-analysis of the abscopal effect in preclinical models: is the biologically effective dose a relevant physical trigger? PLoS One 12(2):e0171559. https://doi.org/10.1371/journal.pone.0171559
Marples B, Lambin P, Skov KA, Joiner MC (1997) Low dose hyper-radiosensitivity and increased radioresistance in mammalian cells. Int J Radiat Biol 71(6):721–735
McLaughlin M, Patin EC, Pedersen M et al (2020) Inflammatory microenvironment remodelling by tumour cells after radiotherapy. Nat Rev Cancer 20(4):203–217. https://doi.org/10.1038/s41568-020-0246-1
Menon H, Chen D, Ramapriyan R et al (2019) Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy. J Immunother Cancer 7(1):237. https://doi.org/10.1186/s40425-019-0718-6
Meric-Bernstam F, Larkin J, Tabernero J, Bonini C (2021) Enhancing anti-tumour efficacy with immunotherapy combinations. Lancet 397(10278):1010–1022. https://doi.org/10.1016/S0140-6736(20)32598-8
Miller BC, Sen DR, Al Abosy R et al (2019) Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol 20(3):326–336. https://doi.org/10.1038/s41590-019-0312-6
Minsky BD, Pajak TF, Ginsberg RJ et al (2002) INT 0123 (Radiation Therapy Oncology Group 94–05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 20(5):1167–1174
Motz GT, Coukos G (2013) Deciphering and reversing tumor immune suppression. Immunity 39(1):61–73. https://doi.org/10.1016/j.immuni.2013.07.005
Nadella V, Singh S, Jain A et al (2018) Low dose radiation primed iNOS + M1macrophages modulate angiogenic programming of tumor derived endothelium. Mol Carcinog 57(11):1664–1671. https://doi.org/10.1002/mc.22879
NCT02642809 (2021) Pembrolizumab with locally delivered radiation therapy for the treatment of metastatic esophageal cancers. https://clinicaltrials.gov/study/NCT02642809
Ngwa W, Irabor OC, Schoenfeld JD, Hesser J, Demaria S, Formenti SC (2018) Using immunotherapy to boost the abscopal effect. Nat Rev Cancer 18(5):313–322. https://doi.org/10.1038/nrc.2018.6
Park B, Yee C, Lee K-M (2014) The effect of radiation on the immune response to cancers. Int J Mol Sci 15(1):927–943. https://doi.org/10.3390/ijms15010927
Patel RR, He K, Barsoumian HB et al (2021a) High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: results of a phase II trial. Radiother Oncol 162:60–67. https://doi.org/10.1016/j.radonc.2021.06.037
Patel RB, Hernandez R, Carlson P et al (2021b) Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade. Sci Transl Med. https://doi.org/10.1126/scitranslmed.abb3631
Peng F, Bao Y, Lian H, Niu S (2021) Increased esophageal perforation after combination of anti-PD-1 immunotherapy with radiotherapy for esophageal carcinoma. Int J Radiat Oncol Biol Phys 111(3):S102
Postow MA, Callahan MK, Barker CA et al (2012) Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366(10):925–931. https://doi.org/10.1056/NEJMoa1112824
Prakash H, Klug F, Nadella V, Mazumdar V, Schmitz-Winnenthal H, Umansky L (2016) Low doses of gamma irradiation potentially modifies immunosuppressive tumor microenvironment by retuning tumor-associated macrophages: lesson from insulinoma. Carcinogenesis 37(3):301–313. https://doi.org/10.1093/carcin/bgw007
Pustylnikov S, Costabile F, Beghi S, Facciabene A (2018) Targeting mitochondria in cancer: current concepts and immunotherapy approaches. Transl Res 202:35–51. https://doi.org/10.1016/j.trsl.2018.07.013
Regine WF, Hanna N, Garofalo MC et al (2007) Low-dose radiotherapy as a chemopotentiator of gemcitabine in tumors of the pancreas or small bowel: a phase I study exploring a new treatment paradigm. Int J Radiat Oncol Biol Phys 68(1):172–177
Rödel F, Frey B, Gaipl U et al (2012a) Modulation of inflammatory immune reactions by low-dose ionizing radiation: molecular mechanisms and clinical application. Curr Med Chem 19(12):1741–1750
Rödel F, Frey B, Manda K et al (2012b) Immunomodulatory properties and molecular effects in inflammatory diseases of low-dose x-irradiation. Front Oncol 2:120. https://doi.org/10.3389/fonc.2012.00120
Rowshanravan B, Halliday N, Sansom DM (2018) CTLA-4: a moving target in immunotherapy. Blood 131(1):58–67. https://doi.org/10.1182/blood-2017-06-741033
Rückert M, Flohr A-S, Hecht M, Gaipl US (2021a) Radiotherapy and the immune system: more than just immune suppression. Stem Cells 39(9):1155–1165. https://doi.org/10.1002/stem.3391
Rückert M, Deloch L, Frey B, Schlücker E, Fietkau R, Gaipl US (2021b) Combinations of radiotherapy with vaccination and immune checkpoint inhibition differently affect primary and abscopal tumor growth and the tumor microenvironment. Cancers. https://doi.org/10.3390/cancers13040714
Sakin A, Ozcelik M, Sahin S et al (2022) The prognostic effect of pretreatment 18F-FDG PET/CT metabolic parameters in locally advanced esophageal squamous cell carcinoma treated with definitive chemoradiotherapy. Surg Oncol 43:101809. https://doi.org/10.1016/j.suronc.2022.101809
Sardaro A, Ferrari C, Carbonara R, Altini C, Lavelli V, Rubini G (2021) Synergism between immunotherapy and radiotherapy in esophageal cancer: an overview of current knowledge and future perspectives. Cancer Biother Radiopharm 36(2):123–132. https://doi.org/10.1089/cbr.2020.3643
Schoenfeld JD, Mahadevan A, Floyd SR et al (2015) Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review. J Immunother Cancer 3:50. https://doi.org/10.1186/s40425-015-0095-8
Scoccianti S, Olmetto E, Pinzi V et al (2021) Immunotherapy in association with stereotactic radiotherapy for non-small cell lung cancer brain metastases: results from a multicentric retrospective study on behalf of AIRO. Neuro Oncol 23(10):1750–1764. https://doi.org/10.1093/neuonc/noab129
Seban R-D, Mezquita L, Berenbaum A et al (2020) Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors. Eur J Nucl Med Mol Imaging 47(5):1147–1157. https://doi.org/10.1007/s00259-019-04615-x
Sha CM, Lehrer EJ, Hwang C et al (2020) Toxicity in combination immune checkpoint inhibitor and radiation therapy: a systematic review and meta-analysis. Radiother Oncol 151:141–148. https://doi.org/10.1016/j.radonc.2020.07.035
Shang B, Liu Y, Jiang S-J, Liu Y (2015) Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep 5:15179. https://doi.org/10.1038/srep15179
Sharabi AB, Lim M, DeWeese TL, Drake CG (2015) Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol 16(13):e498–e509. https://doi.org/10.1016/S1470-2045(15)00007-8
Shaverdian N, Lisberg AE, Bornazyan K et al (2017) Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol 18(7):895–903. https://doi.org/10.1016/S1470-2045(17)30380-7
Shaverdian N, Beattie J, Thor M et al (2020) Safety of thoracic radiotherapy in patients with prior immune-related adverse events from immune checkpoint inhibitors. Ann Oncol 31(12):1719–1724. https://doi.org/10.1016/j.annonc.2020.09.016
Shen L, Kato K, Kim S-B et al (2022) Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): a randomized phase III study. J Clin Oncol 40(26):3065–3076. https://doi.org/10.1200/JCO.21.01926
Shi Z, Zhu X, Ruan C et al (2022) Evaluation of concurrent chemoradiotherapy for survival outcomes in patients with synchronous oligometastatic esophageal squamous cell carcinoma. JAMA Netw Open 5(12):e2244619. https://doi.org/10.1001/jamanetworkopen.2022.44619
Short S, Mayes C, Woodcock M, Johns H, Joiner MC (1999) Low dose hypersensitivity in the T98G human glioblastoma cell line. Int J Radiat Biol 75(7):847–855
Sihag S, Ku GY, Tan KS et al (2021) Safety and feasibility of esophagectomy following combined immunotherapy and chemoradiotherapy for esophageal cancer. J Thorac Cardiovasc Surg. https://doi.org/10.1016/j.jtcvs.2020.11.106
Siva S, MacManus MP, Martin RF, Martin OA (2015) Abscopal effects of radiation therapy: a clinical review for the radiobiologist. Cancer Lett 356(1):82–90. https://doi.org/10.1016/j.canlet.2013.09.018
Stone HB, Peters LJ, Milas L (1979) Effect of host immune capability on radiocurability and subsequent transplantability of a murine fibrosarcoma. J Natl Cancer Inst 63(5):1229–1235
Tagliaferri L, Lancellotta V, Fionda B et al (2022) Immunotherapy and radiotherapy in melanoma: a multidisciplinary comprehensive review. Hum Vaccin Immunother 18(3):1903827. https://doi.org/10.1080/21645515.2021.1903827
Takada K, Toyokawa G, Okamoto T et al (2017) Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on 18 F-fluorodeoxyglucose positron emission tomography/computed tomography. Cancer Med 6(11):2552–2561. https://doi.org/10.1002/cam4.1215
Theelen WSME, Peulen HMU, Lalezari F et al (2019) Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial. JAMA Oncol 5(9):1276–1282. https://doi.org/10.1001/jamaoncol.2019.1478
Theelen WSME, Chen D, Verma V et al (2021) Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med 9(5):467–475. https://doi.org/10.1016/S2213-2600(20)30391-X
Thurin M, Cesano A, Marincola F (2020) Biomarkers for immunotherapy of cancer. Methods in molecular biology. Using RNA sequencing to characterize the tumor microenvironment, New York, pp 245–272
Voong KR, Hazell SZ, Fu W et al (2019) Relationship between prior radiotherapy and checkpoint-inhibitor pneumonitis in patients with advanced non-small-cell lung cancer. Clin Lung Cancer 20(4):e470–e479. https://doi.org/10.1016/j.cllc.2019.02.018
Voorwerk L, Slagter M, Horlings HM et al (2019) Publisher correction: immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat Med 25(7):1175. https://doi.org/10.1038/s41591-019-0520-5
Wang S-J, Haffty B (2018) Radiotherapy as a new player in immuno-oncology. Cancers (basel). https://doi.org/10.3390/cancers10120515
Wang D, Zhang X, Gao Y et al (2020) Research progress and existing problems for abscopal effect. Cancer Manag Res 12:6695–6706. https://doi.org/10.2147/CMAR.S245426
Wang X, Yu N, Cheng G et al (2022a) Prognostic value of circulating tumour DNA during post-radiotherapy surveillance in locally advanced esophageal squamous cell carcinoma. Clin Transl Med 12(11):e1116. https://doi.org/10.1002/ctm2.1116
Wang H, Li S, Liu T, Chen J, Dang J (2022b) Neoadjuvant immune checkpoint inhibitor in combination with chemotherapy or chemoradiotherapy in resectable esophageal cancer: a systematic review and meta-analysis. Front Immunol 13:998620. https://doi.org/10.3389/fimmu.2022.998620
Wang Y, Zhang T, Huang Y et al (2022c) Real-world safety and efficacy of consolidation durvalumab after chemoradiation therapy for stage III non-small cell lung cancer: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys 112(5):1154–1164. https://doi.org/10.1016/j.ijrobp.2021.12.150
Wei J, Montalvo-Ortiz W, Yu L et al (2021) Sequence of αPD-1 relative to local tumor irradiation determines the induction of abscopal antitumor immune responses. Sci Immunol. https://doi.org/10.1126/sciimmunol.abg0117
Weichselbaum RR, Liang H, Deng L, Fu Y-X (2017) Radiotherapy and immunotherapy: a beneficial liaison? Nat Rev Clin Oncol 14(6):365–379. https://doi.org/10.1038/nrclinonc.2016.211
Welsh JW, Tang C, de Groot P et al (2019) Phase II trial of ipilimumab with stereotactic radiation therapy for metastatic disease: outcomes, toxicities, and low-dose radiation-related abscopal responses. Cancer Immunol Res 7(12):1903–1909. https://doi.org/10.1158/2326-6066.CIR-18-0793
Woody S, Hegde A, Arastu H et al (2022) Survival is worse in patients completing immunotherapy prior to SBRT/SRS compared to those receiving it concurrently or after. Front Oncol 12:785350. https://doi.org/10.3389/fonc.2022.785350
Worrell SG, Towe CW, Dorth JA, Machtay M, Perry Y, Linden PA (2020) Higher doses of neoadjuvant radiation for esophageal cancer do not affect the pathologic complete response rate or survival: a propensity-matched analysis. Ann Surg Oncol 27(2):500–508. https://doi.org/10.1245/s10434-019-07849-z
Wu X, Ke X, Ni Y et al (2020) Tumor-infiltrating immune cells and PD-L1 as prognostic biomarkers in primary esophageal small cell carcinoma. J Immunol Res 2020:8884683. https://doi.org/10.1155/2020/8884683
Wu J, Deng R, Ni T et al (2022) Efficacy and safety of radiotherapy/chemoradiotherapy combined with immune checkpoint inhibitors for locally advanced stages of esophageal cancer: a systematic review and meta-analysis. Front Oncol 12:887525. https://doi.org/10.3389/fonc.2022.887525
Wu X, Li Y, Zhang K et al (2023) Immunotherapy with or without radiotherapy for metastatic or recurrent esophageal squamous cell carcinoma: a real-world study. Clin Transl Radiat Oncol 38:130–137. https://doi.org/10.1016/j.ctro.2022.10.011
Xu Y, Dong B, Zhu W et al (2022) A phase III multicenter randomized clinical trial of 60 Gy versus 50 Gy radiation dose in concurrent chemoradiotherapy for inoperable esophageal squamous cell carcinoma. Clin Cancer Res 28(9):1792–1799. https://doi.org/10.1158/1078-0432.CCR-21-3843
Yan T, Cui H, Zhou Y et al (2019) Multi-region sequencing unveils novel actionable targets and spatial heterogeneity in esophageal squamous cell carcinoma. Nat Commun 10(1):1670. https://doi.org/10.1038/s41467-019-09255-1
Yan X, Duan H, Ni Y et al (2022) Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: a prospective, single-arm, phase II study (TD-NICE). Int J Surg 103:106680. https://doi.org/10.1016/j.ijsu.2022.106680
Yarchoan M, Hopkins A, Jaffee EM (2017) Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med 377(25):2500–2501. https://doi.org/10.1056/NEJMc1713444
Yin Z, Li C, Wang J, Xue L (2019) Myeloid-derived suppressor cells: roles in the tumor microenvironment and tumor radiotherapy. Int J Cancer 144(5):933–946. https://doi.org/10.1002/ijc.31744
Yin L, Xue J, Li R et al (2020) Effect of low-dose radiation therapy on abscopal responses to hypofractionated radiation therapy and anti-PD1 in mice and patients with non-small cell lung cancer. Int J Radiat Oncol Biol Phys 108(1):212–224. https://doi.org/10.1016/j.ijrobp.2020.05.002
Zhai D, An D, Wan C, Yang K (2022) Radiotherapy: brightness and darkness in the era of immunotherapy. Transl Oncol 19:101366. https://doi.org/10.1016/j.tranon.2022.101366
Zhang W, Pang Q, Zhang X et al (2017) Programmed death-ligand 1 is prognostic factor in esophageal squamous cell carcinoma and is associated with epidermal growth factor receptor. Cancer Sci 108(4):590–597. https://doi.org/10.1111/cas.13197
Zhang W, Yan C, Gao X et al (2021) Safety and feasibility of radiotherapy plus camrelizumab for locally advanced esophageal squamous cell carcinoma. Oncologist 26(7):e1110–e1124. https://doi.org/10.1002/onco.13797
Zhao X, Kang J, Zhao R (2018) Abscopal effect of radiation on lymph node metastasis in esophageal carcinoma: a case report and literature review. Oncol Lett 16(3):3555–3560. https://doi.org/10.3892/ol.2018.9084
Zheng S, Shen T, Liu Q et al (2021) CXCL6 fuels the growth and metastases of esophageal squamous cell carcinoma cells both in vitro and in vivo through upregulation of PD-L1 via activation of STAT3 pathway. J Cell Physiol 236(7):5373–5386. https://doi.org/10.1002/jcp.30236
Zhou X, Yao Z, Bai H et al (2021) Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. Lancet Oncol 22(9):1265–1274. https://doi.org/10.1016/S1470-2045(21)00333-8
Zhu Y, Wen J, Li Q et al (2023) Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trial. Lancet Oncol 24(4):371–382. https://doi.org/10.1016/S1470-2045(23)00060-8
Acknowledgements
We acknowledge the Department of Oncology of Weifang Hospital of Traditional Chinese Medicine.
Funding
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by Shandong Provincial Health Commission (Grant number Z-2023064).
Author information
Authors and Affiliations
Contributions
XZ: writing—original draft preparation. XC: supervision, conceptualization, methodology, writing—reviewing and editing. CY: supervision, writing—reviewing and editing. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Ethics approval and consent to participate
Not applicable.
Patient consent for publication
Not applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Zhang, X., Cai, X. & Yan, C. Opportunities and challenges in combining immunotherapy and radiotherapy in esophageal cancer. J Cancer Res Clin Oncol 149, 18253–18270 (2023). https://doi.org/10.1007/s00432-023-05499-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-023-05499-z